The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Trial Physician / Study Coordinator
Amy Mottl
Email Phone (919) 445-2641Site Name
University of North Carolina at Chapel Hill
7024 Burnett-Womack bldg, CB #7155, Chapel Hill, NC 27599
The PODO Trial
Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis
The purpose of this Phase 2 adaptive study is to evaluate PF-06730512 following multiple intravenous infusions in adult patients with primary FSGS. In addition, the intention is to obtain an early indication of efficacy (how well the drug works at improving Urine Protein to Creatinine Ratio).
Eligibility Criteria
Patient Population
Primary focal segmental glomerulosclerosis (FSGS)
About the Drug
What is involved for the patient
Patients will participate for 13 weeks, receiving an intravenous infusion of the study drug weekly.
Sponsor
Pfizer Inc.
Target Enrollment
44
Estimated End Date
May, 2023
About the Trial
Study Drug
PF-06730512
Study Goal
To evaluate the safety, tolerability, and possibly efficacy of PF-06730512 in patients with FSGS.
About the drug or intervention
PF-06730512 works as an antagonist, meaning it possibly reduces the biologic activity that is associated with FSGS.